Lipigon Pharmaceuticals AB Strategic Asset Allocation Index
Lipigon Pharmaceuticals AB strategic asset allocation index. Lipigon Pharmaceuticals AB (LPGO) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of Skr61.00K plus long-term investments of Skr-) total Skr61.00K, measured against net assets of Skr27.59 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See LPGO equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Lipigon Pharmaceuticals AB (2021–2022)
Strategic asset allocation index of Lipigon Pharmaceuticals AB from 2021 to 2022. This chart shows how Lipigon Pharmaceuticals AB's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of Skr61.00K against net assets of Skr27.59 Million SEK. Check LPGO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Lipigon Pharmaceuticals AB Strategic Asset Allocation Index by Year (2021–2022)
Lipigon Pharmaceuticals AB strategic asset allocation index by year from 2021 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Lipigon Pharmaceuticals AB from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Lipigon Pharmaceuticals AB stock valuation.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.9% | Skr72.00K | Skr72.00K | Skr- | Skr3.87 Million | ▲ +1.4 pp |
| 2021 | 0.4% | Skr96.00K | Skr96.00K | Skr- | Skr22.96 Million | — |